Abstract 197P
Background
Tumor mutation burden, intratumor heterogeneity and the cancer related immune infiltrate are associated with response to target and immune therapies in several cancer types. The aim of this study is to establish a computational pathology (CPath) pipeline for investigating useful histopathological features in hematoxylin and eosin (H&E) whole slide images (WSIs). The pipeline allows for the segmentation and classification of nuclei. As an application, a machine learning approach is used to quantify intratumor heterogeneity (ITH) and tumor-infiltrating lymphocyte (TIL) scores.
Methods
We randomly selected 178 invasive ductal carcinomas WSIs from the TCGA database to process. Image annotation and nuclei detection were performed on QuPath by a pathologist using StarDist and used to train a SVM-based nuclei type classifier. The classifier was trained to distinguish between tumor, lymphocyte, and stroma. A total of 113.211 nuclei images were extracted using OpenSlide and used to train an autoencoder for dimensionality reduction. The variability of the WSIs was computed by applying a statistical measure of dispersion to the feature vectors. The TIL score was computed as the average minimum distance between a tumor cell and its nearest lymphocyte neighbor. We used the mutation burden, the ITH, PAM50 classification, nuclear and histological grades data from [https://doi.org/10.1038/nm.3984] to validate our ITH score. The percentage of infiltrating lymphocytes inferred by the quanTIseq pipeline based on RNAseq data was used to validate the SVM model.
Results
The nuclei classifier achieved 88% accuracy on the test set and the 96%/92% sensitivity to tumor/lymphocyte on a validation dataset. The mean squared error of the autoencoder was 0.0004 in the test set. The ITH score was associated with the clonal number of a tumor (x2 = 8.8, p= 0.03). Finally, we observed a positive correlation between the TIL/tumor ratio inferred by the CPath pipeline and the total number of T lymphocytes inferred by quanTIseq (Spearman= 0. 34, p < 0.0001).
Conclusions
We explored a CPath pipeline for detecting and classifying nuclei. The pipeline was used to compute ITH and TIL scores which correlated with validation data. Thus, validating our pipeline.
Legal entity responsible for the study
D.G. Tiezzi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - High-dimensional analysis of tumor infiltrating immune cells reveals major differences in the tumor immune microenvironments of pleural mesothelioma and lung cancer
Presenter: Angelica Rigutto
Session: Poster Display
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display